Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P48060
UPID:
GLIP1_HUMAN
Alternative names:
Protein RTVP-1
Alternative UPACC:
P48060; A7YET6; F8VUC2; Q15409; Q969K2
Background:
Glioma pathogenesis-related protein 1, also known as Protein RTVP-1, plays a crucial role in the biological mechanisms underlying glioma development. Its unique position in cellular pathways highlights its potential as a key player in tumor biology.
Therapeutic significance:
Understanding the role of Glioma pathogenesis-related protein 1 could open doors to potential therapeutic strategies. Its involvement in glioma suggests a promising avenue for targeted therapy development, aiming to disrupt the pathways contributing to tumor growth.